Redefining Treatment Expectations in Moderate-to-Severe Psoriasis Dermatologists participating in this symposium will:
- Discuss practical management issues with biologic agents in the treatment of psoriatic disease based on extensive US experience,
- Recognize the key safety issues with TNF antagonists currently available in Canada,
- Obtain pearls on how to incorporate biologics into their own practice through an interactive panel discussion
Dr. Kim Papp, Chair
Dr. Brian Feagan
Dr. Kristian Reich
Dr. Kam Shojania
Dr. Norman Wasel
9:30 - 9:35
Welcome
Dr. Kim Papp, Chair
9:35 - 10:00
The Use of TNF Blockers in Chronic Inflammatory Disease: What are the
Important Safety Issues?
Dr. Brian Feagan
10:00 - 10:15
Changing Paradigms in Moderate-to-Severe Psoriasis
Dr. Norman Wasel
10:15 - 10:40
Unmet Needs of Psoriasis and the Promise of Biologics
Dr. Kristian Reich
10:40 - 10:55
Remicade Infusion Network:
Experience in the Rheumatology Community
Dr. Kam Shojania
10:55 - 11:00
Closing Remarks
Dr. Kim Papp, Chair
2:00 – 3:30
From Trial to Clinic: A Year of Raptiva Experience in Canada
Room: Macdonald ABCD, Fairmont Chateau Whistler Resort
Session Objectives:
Following this workshop, the attendee will be able to:
- Define the appropriate patients for biological agents
- Apply practical considerations in the use of biologics for the treatment of psoriasis, with a focus on Raptiva
- Review the efficacy and safety of Raptiva as observed in Canadian clinical practice
Efalizumab for Patients with Palmoplantar Psoriasis
Dr. Richard Langley
4:45 - 5:05
Adalimumab in Psoriasis: CHAMPION Phase III Trial Results
Dr. Richard Langley
5:05 - 5:25
Cosmeceuticals - the Latest Novel Human Skin Pigmentation Therapy
Dr. Lawrence F. Eichenfield,
Dr. Neil Shear
5:25 - 5:45
Panel and Questions
Friday, October 27, 2006 – Salle de Bal Centre & Est
9:30 – 11:00
New Advances in Photobiology and Photoprotection
Room: Frontenac C, Fairmont Chateau Whistler Resort
Session Objectives:
Dermatologists participating in this symposium will :
- have an update of the skin damages caused by UVA radiation
- recognize the importance of UVA protection and the need for sunscreens with broad spectrum UVA/UVB protection
- acquire knowledge of UVA protection evaluation with PPD ( Persistent Pigment Darkening ) method
- evaluate the efficacy of different sunscreens formulations and the benefits of the new filter Mexoryl XL
Dr Jason Rivers , Chair;
Dr Robert Bissonnette;
Anny Fourtanier, L'Oreal Recherche;
Dominique Moyal, L'Oreal Recherche;
Jean Louis Refregier, L'Oreal Recherche
IMPORTANCE OF UVA PROTECTION: SKIN CANCER AND BEYOND
Dr. Robert Bissonnette
UVA PHOTOPROTECTION EVALUATION
Dominique Moyal
NEW ADVANCES IN SUN CARE PRODUCTS: IMPROVED UVA PROTECTION WITH MEXORYL XL
Jean Louis Refregier
11:30 – 1:30
Biologics and Psoriatic Disease: Practical Management Issues and Clinical Update
Room: Macdonald ABCD, Fairmont Chateau Whistler Resort
Session Objectives:
Dermatologists participating in this symposium will;
- Discuss practical management issues with biologic agents in the treatment of psoriatic disease based on extensive US experience,
- Recognize the key safety issues with TNF antagonists currently available in Canada,
- Obtain pearls on how to incorporate biologics into their own practice through an interactive panel discussion
Dr. Richard Thomas Dr. Joseph Jorizzo Dr. Richard Langley
Clinical Trial Workshop: Optimizing Your Research Site Room: Macdonald E, Fairmont Chateau Whistler ResortDirected by:
Lynne Bulger, Director Medical Affairs, Barrier Therapeutics
Paul Kidson, Director Medical Affairs, LEO Pharma
1. Site Selection: The CRO Perspective
Doug Keller, President, Moncoa Medical Research Inc.
Site Selection: The Industry Perspective
Todd Georgieff, Senior Manager, Clinical Operations, Abbott
Lynne Bulger, Director Medical Affairs, Barrier
Doug Keller
Todd Georgieff
2
Multidisciplinary Co-operation: Dermatology and Rheumatology
